Uveal melanoma is the most common ocular tumor with frequent metastatic spread to the liver. Immune checkpoint inhibitors have demonstrated poor results in this disease. The addition of hepatic radiotherapy to anti-PD-1 could enhance the sensitivity to immunotherapy. In this study, patients treated with pembrolizumab and who have undergone hepatic radiotherapy have been retrospectively evaluated. Twenty-two patients have been considered. Six patients (27.3%) achieved a partial response and 3 (13.6%) a stable disease. Disease control rate was 40.9%. Thirteen patients (59.1%) had progression as best response. The median PFS was 4.8 months and 6 months PFS rate 45.4%. The median OS was 21.2 months, while 1 year OS rate was 72.7%. Longer survival was observed in patients who achieved a partial response on irradiated metastases (HR 0.23, 95% CI 0.06-0.83) or progressed after 6 months (HR 0.12-95% CI 0.03-0.44). No radiotherapy-related or grade 3-4 adverse events were reported. This study demonstrates that the addition of hepatic radiotherapy to anti-PD-1 treatment can be a valid option for the treatment of metastatic uveal melanoma, particularly for HLA A 02:01 negative patients. Prospective studies should be conducted to confirm these data.

Rossi, E., Cellini, F., Pagliara, M. M., Sammarco, M. G., Pedone, R. R., Lancellotta, V., Tagliaferri, L., Quirino, M., Gambacorta, M. A., Blasi, M. A., Tortora, G., Schinzari, G., Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients, <<CANCERS>>, 2023; 15 (2): 493-N/A. [doi:10.3390/cancers15020493] [https://hdl.handle.net/10807/232384]

Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients

Rossi, Ernesto
;
Cellini, Francesco;Pagliara, Monica Maria;Sammarco, Maria Grazia;Pedone, Romina Rose;Lancellotta, Valentina;Tagliaferri, Luca;Quirino, Michela;Gambacorta, Maria Antonietta;Blasi, Maria Antonietta;Tortora, Giampaolo;Schinzari, Giovanni
2023

Abstract

Uveal melanoma is the most common ocular tumor with frequent metastatic spread to the liver. Immune checkpoint inhibitors have demonstrated poor results in this disease. The addition of hepatic radiotherapy to anti-PD-1 could enhance the sensitivity to immunotherapy. In this study, patients treated with pembrolizumab and who have undergone hepatic radiotherapy have been retrospectively evaluated. Twenty-two patients have been considered. Six patients (27.3%) achieved a partial response and 3 (13.6%) a stable disease. Disease control rate was 40.9%. Thirteen patients (59.1%) had progression as best response. The median PFS was 4.8 months and 6 months PFS rate 45.4%. The median OS was 21.2 months, while 1 year OS rate was 72.7%. Longer survival was observed in patients who achieved a partial response on irradiated metastases (HR 0.23, 95% CI 0.06-0.83) or progressed after 6 months (HR 0.12-95% CI 0.03-0.44). No radiotherapy-related or grade 3-4 adverse events were reported. This study demonstrates that the addition of hepatic radiotherapy to anti-PD-1 treatment can be a valid option for the treatment of metastatic uveal melanoma, particularly for HLA A 02:01 negative patients. Prospective studies should be conducted to confirm these data.
2023
Inglese
Rossi, E., Cellini, F., Pagliara, M. M., Sammarco, M. G., Pedone, R. R., Lancellotta, V., Tagliaferri, L., Quirino, M., Gambacorta, M. A., Blasi, M. A., Tortora, G., Schinzari, G., Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients, <<CANCERS>>, 2023; 15 (2): 493-N/A. [doi:10.3390/cancers15020493] [https://hdl.handle.net/10807/232384]
File in questo prodotto:
File Dimensione Formato  
cancers-15-00493.pdf

accesso aperto

Descrizione: Paper
Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.28 MB
Formato Adobe PDF
2.28 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/232384
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 2
social impact